This website is no longer being updated. Please visit GBCHealth’s new website at:


Pfizer Inc


Pfizer Inc is a research-based, global pharmaceutical company. Pfizer discovers and develops innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Their products are available in more than 150 countries.

HIV/AIDS Profile

Pfizer's "Diflucan Partnership" provides the anti-fungal medicine Diflucan - free of charge - to help fight two of the most common opportunistic infections associated with HIV/AIDS: cryptococcal meningitis and esophageal candidiasis. Pfizer also provides the training and education necessary to make the program a success. Based initially on its partnership with the South African government, Pfizer is expanding the program to the least developed countries most in need, particularly in sub-Saharan Africa.

Pfizer Foundation
Pfizer Inc. and the Pfizer Foundation are also funding the Academic Alliance for AIDS Care and Prevention in Africa, a collaboration of Ugandan and North American infectious disease experts. In partnership with Makerere University Medical School, the Alliance, Pfizer Inc. and the Pfizer Foundation will help build, equip, and operate a new AIDS prevention, treatment, and training center in Kampala, Uganda. The center will not only treat patients, but also serve as a regional training center for African health care practitioners.

Through these and other initiatives, such as the funding of a "best practices" study in Uganda, Pfizer is working in close partnership with UNAIDS, the World Health Organization, and non-governmental organizations.

The Pfizer Foundation also makes $1.6 million available for health literacy programs, targeting countries where the Diflucan program is operating.

Malaria Profile

As part of an estimated 5-year, $3 million/year pilot project, Pfizer is working with its country offices and on-the-ground partners to increase the percentage of patients who seek proper malaria care and enhance the capacity of the informal sector to serve as a vehicle for the effective delivery of anti-malarial medicine.